The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis

Current Biology

Volumn 9, Issue 24, 1999, Pages 1441-1447

  Powell, William C ^a,b   Fingleton, Barbara ^a   Wilson, Carole L ^a,c   Boothby, Mark ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; RODENTIA;

EID: 0033576645     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(00)80113-X     Document Type: Article

References (40)

1. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME: Apoptosis signaling by death receptors. Eur J Biochem 1998, 254:439-459.
2. French LE, Hahne M, Viand I, Radlgruber G, Zanone R, Becker K, et al.: Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996, 133:335-343.
3. Xerri L, Devilard E, Hassoun J, Mawas C, Birg F: Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 1997, 50:87-91.
4. Tenniswood M: Apoptosis, tumour invasion and prostate cancer. Br J Urol 1997, 79:27-34.
5. Suzuki A, Matsuzawa A, Iguchi T: Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 1996, 13:31-37.
6. Woolveridge I, Taylor MF, Wu FC, Morris ID: Apoptosis and related genes in the rat ventral prostate following androgen ablation in response to ethane dimethanesulfonate. Prostate 1998, 36:23-30.
7. de la Taille A, Chen MW, Shabsigh A, Bagiella E, Kiss A, Buttyan R: Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. Prostate 1999, 40:89-96.
8. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al.: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995, 182:1777-1783.
9. Mariani SM, Matiba B, Baumler C, Krammer PH: Regulation of cell surface APO-1/fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995, 25:2303-2307.
10. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995, 14:1129-1135.
11. Suda T, Tanaka M, Miwa K, Nagata S: Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 1996, 157:3918-3924.
12. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al.: Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998, 187:1205-1213.
13. Powell WC, Domann FE Jr, Mitchen JM, Matrisian LM, Nagle RB, Bowden GT, et al.: Matrilysin expression in the involuting rat ventral prostate. Prostate 1996, 29:159-168.
14. Wilson CL, Matrisian LM: Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996, 28:123-136.
15. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al.: Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994, 370:555-557.
16. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nat Med 1998, 4:31-36.
17. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M: Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 1998, 153:1947-1956.
18. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997, 385:729-733.
19. Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen WJ, et al.: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385:733-736.
20. Baragi VM, Fliszar CJ, Conroy MC, Ye Q-Z, Shipley JM, Welgus HG: Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. J Biol Chem 1994, 269:12692-12697.
21. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, et al.: The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994, 1:131 -136.
22. Larregina AT, Morelli AE, Dewey RA, Castro MG, Fontana A, Lowenstein PR: FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors. Gene Therapy 1998, 5:563-568.
23. Saarialho-Kere UK, Crouch EC, Parks WC: The matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995, 105:190-196.
24. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997, 94:1402-1407.
25. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM: Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 1997, 138:4902-4911.
26. Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995, 267:891 -893.
27. Witty JP, Lempka T, Coffey RJ, Jr, Matrisian LM: Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 1995, 55:1401-1406.
28. Alexander CM, Howard EW, Bissell MJ, Werb Z: Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol 1996, 135:1669-1677.
29. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al.: MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
30. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al.: Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538-549.
31. Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998, 101:1478-1487.
32. Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124:619-626.
33. Strater J, Wedding U, Barth TF, Koretz K, Elsing C, Moller P: Rapid onset of apoptosis in vitro follows disruption of β1 integrin/matrix interactions in human colonic crypt cells. Gastroenterology 1996, 110:1776-1784.
34. Oyaizu N, Kayagaki N, Yagita H, Pahwa S, Ikawa Y: Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: The membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem Biophys Res Commun 1997, 238:670-675.
35. Gong W, Pecci A, Roth S, Lahme B, Beato M, Gressner AM: Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand. Hepatology 1998, 28:492-502.
36. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rosejohn S, Massague J: Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996, 271:11376-11382.
37. Levi E, Fridman R, Miao H-Q, Ma Y-S, Yayon A, Vlodavsky I, et al.: Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996, 93:7069-7074.
38. Smith MM, Shi L, Navre M: Rapid identification of highly active and selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries. J Biol Chem 1995, 270:6440-6449.
39. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, et al.: Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 1995, 10:1269-1274.
40. Barnett J, Straub K, Nguyen B, Chow J, Suttman R, Thompson K, et al.: Production, purification, and characterization of human matrilysin (PUMP) from recombinant Chinese hamster ovary cells. Prof Exp Purif 1994, 5:27-36.